Caribou Biosciences(CRBU)
Focus: Caribou Biosciences is a public biotech company specializing in cellular engineering tools based on CRISPR gene-editing technology, focused on developing allogeneic CAR-T cell therapies for hematologic and oncologic indications. The company operates as a mid-cap biotech platform with early-stage pipeline assets.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3
Should You Work at Caribou Biosciences?
AI assessmentCaribou offers frontier CRISPR science and public-company credibility, but severe cash depletion, early-stage pipeline, and reduced hiring create material restructuring risk for career continuity.
Why Work Here
- Cutting-edge CRISPR platform technology with foundational IP in cellular engineering attracts scientists pursuing next-generation gene therapy
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$10M
Pipeline & Clinical Trials
Caribou-sponsored investigational therapy
Lymphoma, Non-HodgkinClinical Trials (1)
NCT05332054Long-Term Follow-up Study
N/AHelp build intelligence for Caribou Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.